Interventional Radiology for the Treatment of Symptomatic Portal Hypertension in Patients With Cavernous Transformation of Portal Vein

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02504034

Enrollment

150

Registered

2015-07-21

Start date

2010-10-31

Completion date

Unknown

Last updated

2015-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Portal Vein, Cavernous Transformation Of, Hypertension, Portal

Keywords

Portal Vein, Cavernous Transformation Of, Hypertension, Portal, Radiology, Interventional, Portalsystemic shunt

Brief summary

To evaluate the values of portosystemic shunt and other interventional radiology approaches for treatment of symptomatic portal hypertension in patients with cavernous transformation of portal vein.

Interventions

PROCEDURETranshepatic portosystemic shunt

Portal vein (PV) was punctured with a 22-gauge chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 6-French sheath inserted over the wire. Then middle hepatic vein (MHV) was punctured with a 20-gauge reformed needle through the transhepatic sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm-long stiff shaft wire was introduced through the transjugular sheath and manipulated into main portal vein (MPV) and then into SMV. The parenchymal tract was dilated with balloon catheter, then one or more bare metal stents and one or more covered stents were inserted to line the parenchymal tract.

DEVICE6-French sheath

DEVICE22-gauge chiba needle

DEVICE260-cm-long stiff shaft wire

DEVICEBalloon catheter

DEVICEBare metal stent

DEVICECovered stent

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Years to 80 Years

Healthy volunteers

Inclusion criteria

* All patients with portal hypertention who have enough image information to confirm cavernous transformation of portal vein.

Exclusion criteria

* Patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs.

Design outcomes

Primary

Measure	Time frame	Description
Incidence Rate of Gastrointestinal Bleeding	1 month	No gastrointestinal bleeding proved by patients' symptoms (If the patients had the history of gastrointestinal bleeding before)
Ascites Volume (mL)	1 month	No ascites proved by CT scanning or ultrasound (If the patients had the history of ascites before)

Countries

China

Contacts

Primary ContactZaibo Jiang, MD.

jiangzaibo@aliyun.com+86 020 85252066

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026